언어 선택

HLA-A*1101 & B2M & EBV (AVFDRKSDAK)

HLA-A*1101 & B2M & EBV (AVFDRKSDAK) 제품 목록

속성
Protein (2)
제품 라이브러리
온라인 (2)
종
Human (2)
태그
His Tag & Avi Tag (1)His Tag (1)
마커
Biotin-labeled (1)PE Labeled (1)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
HLE-H82E5	Human	HEK293	Biotinylated Human HLA-A*11:01&B2M&EBV (AVFDRKSDAK) Complex Protein (Monomer, MALS verified)
HLE-HP2H4	Human	HEK293	PE-Labeled Human HLA-A*11:01&B2M&EBV (AVFDRKSDAK) Tetramer Protein

총 수량2

HLA-A*1101 & B2M & EBV (AVFDRKSDAK)분자 배경

Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. The Human HLA-A*1101 EBV (AVFDRKSDAK) complex protein is a complex of HLA-A*1101 of the MHC Class I, B2M and AVFDRKSDAK peptide of the EBV.

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Alintegimod	7HP349; 7-HP-349; 7HP-349	Phase 2 Clinical	7 Hills Pharma LLC	Kidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Lifitegrast	SHP-606; SAR-1119; SAR-1118; OJL-332; SPD-606	Approved	Shire Development Llc	Xiidra	United States	Dry Eye Syndromes	Bausch And Lomb Inc	2016-07-11	Keratoconjunctivitis Sicca; Graft vs Host Disease; Dry Eye Syndromes; Diabetic macular oedema; Conjunctivitis, Allergic; Xerophthalmia	상세